Treace Medical Concepts, Inc. Increase (Decrease) in Accounts Receivable
Treace Medical Concepts, Inc. (TMCI) reported Increase (Decrease) in Accounts Receivable of -$13.18 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-07
- Treace Medical Concepts, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was -$1.50M.
- Treace Medical Concepts, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was -$11.69M.
- Treace Medical Concepts, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $9.52M, a 44.64% decline year-over-year.
- Treace Medical Concepts, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $2.56M.
- Treace Medical Concepts, Inc. increase (decrease) in accounts receivable for fiscal 2025 was $2.09M, a 63.25% decline from fiscal 2024.
- Treace Medical Concepts, Inc. increase (decrease) in accounts receivable for fiscal 2024 was $5.69M, a 38.86% decline from fiscal 2023.
- Treace Medical Concepts, Inc. increase (decrease) in accounts receivable for fiscal 2023 was $9.30M, a 15.74% decline from fiscal 2022.
- Treace Medical Concepts, Inc. increase (decrease) in accounts receivable for fiscal 2022 was $11.04M, a 161.22% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$13.18M 10-Q · filed 2026-08-07 | -$3.66M derived: sum of 3 quarters · filed 2026-08-07 | -$1.10M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | -$11.69M 10-Q · filed 2026-05-08 | -$2.17M derived: sum of 2 quarters · filed 2026-05-08 | $390.00K derived: sum of 3 quarters · filed 2026-05-08 | -$306.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $9.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $12.07M derived: sum of 2 quarters · filed 2026-02-27 | $11.38M derived: sum of 3 quarters · filed 2026-08-07 | $2.09M 10-K · filed 2026-02-27 |
| 2025-09-30 | $2.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.86M derived: sum of 2 quarters · filed 2026-08-07 | -$7.43M 10-Q · filed 2025-11-06 | $9.76M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | -$696.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$9.98M 10-Q · filed 2026-08-07 | $7.21M derived: sum of 3 quarters · filed 2026-08-07 | $6.00M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | -$9.29M 10-Q · filed 2026-05-08 | $7.90M derived: sum of 2 quarters · filed 2026-05-08 | $6.70M derived: sum of 3 quarters · filed 2026-05-08 | $4.22M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $17.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $15.98M derived: sum of 2 quarters · filed 2026-02-27 | $13.51M derived: sum of 3 quarters · filed 2026-02-27 | $5.69M 10-K · filed 2026-02-27 |
| 2024-09-30 | -$1.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$3.68M derived: sum of 2 quarters · filed 2025-11-06 | -$11.51M 10-Q · filed 2025-11-06 | $1.92M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | -$2.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$10.30M 10-Q · filed 2025-08-07 | $3.13M derived: sum of 3 quarters · filed 2026-02-27 | $890.00K derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | -$7.82M 10-Q · filed 2025-05-08 | $5.60M derived: sum of 2 quarters · filed 2026-02-27 | $3.37M derived: sum of 3 quarters · filed 2026-02-27 | $5.27M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $13.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $11.19M derived: sum of 2 quarters · filed 2026-02-27 | $13.09M derived: sum of 3 quarters · filed 2026-02-27 | $9.30M 10-K · filed 2026-02-27 |
| 2023-09-30 | -$2.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$328.00K derived: sum of 2 quarters · filed 2024-11-05 | -$4.12M 10-Q · filed 2024-11-05 | $6.98M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $1.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$1.89M 10-Q · filed 2024-08-06 | $9.21M derived: sum of 3 quarters · filed 2025-02-27 | $11.27M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$3.79M 10-Q · filed 2024-05-07 | $7.30M derived: sum of 2 quarters · filed 2025-02-27 | $9.36M derived: sum of 3 quarters · filed 2025-02-27 | $9.79M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $11.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $13.15M derived: sum of 2 quarters · filed 2025-02-27 | $13.58M derived: sum of 3 quarters · filed 2025-02-27 | $11.04M 10-K · filed 2025-02-27 |
| 2022-09-30 | $2.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $2.48M derived: sum of 2 quarters · filed 2023-11-09 | -$58.00K 10-Q · filed 2023-11-09 | $6.92M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $430.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$2.11M 10-Q · filed 2023-08-09 | $4.86M derived: sum of 3 quarters · filed 2024-02-27 | $6.63M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$2.54M 10-Q · filed 2023-05-09 | $4.43M derived: sum of 2 quarters · filed 2024-02-27 | $6.20M derived: sum of 3 quarters · filed 2024-02-27 | $5.45M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $6.97M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $8.74M derived: sum of 2 quarters · filed 2024-02-27 | $8.00M derived: sum of 3 quarters · filed 2024-02-27 | $4.23M 10-K · filed 2024-02-27 |
| 2021-09-30 | $1.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $1.02M derived: sum of 2 quarters · filed 2022-11-09 | -$2.75M 10-Q · filed 2022-11-09 | $2.31M derived: sum of 4 quarters · filed 2023-03-08 |
| 2021-06-30 | -$742.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$4.51M 10-Q · filed 2022-08-10 | $544.00K derived: sum of 3 quarters · filed 2023-03-08 | $3.31M derived: sum of 4 quarters · filed 2023-03-08 |
| 2021-03-31 | -$3.77M 10-Q · filed 2022-05-06 | $1.29M derived: sum of 2 quarters · filed 2023-03-08 | $4.05M derived: sum of 3 quarters · filed 2023-03-08 | $4.33M derived: sum of 4 quarters · filed 2023-03-08 |
| 2020-12-31 | $5.05M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $7.82M derived: sum of 2 quarters · filed 2023-03-08 | $8.10M derived: sum of 3 quarters · filed 2023-03-08 | $4.29M 10-K · filed 2023-03-08 |
| 2020-09-30 | $2.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $3.04M derived: sum of 2 quarters · filed 2021-11-04 | -$765.00K 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $275.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$3.53M 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | -$3.81M 10-Q · filed 2021-05-25 | |||
| 2019-12-31 | $6.02M 10-K · filed 2022-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |